Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $83.9952W HIGH $226.16
Volume
121.21 K
Value Traded
71.92 M
Short % Float
27.18%
Days to Cover
8.2
-9.73%Week
-7.63%1 Month
+15.25%3 Month
+70.3%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.27 B
EPS (TTM)
26.27
P/E Ratio
7.08
Ent. Value
1.11 B
Total Shares
6.85 M
Float Shares
4.60 M
Insiders
32.87%
Institutions
43.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NUTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Nutex Health Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How NUTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Nutex Health Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NUTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Saunders Scott JDirector | Sell | -203 400 held | $214.25 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NUTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NUTX for Q2 2026. | ||||
NUTX Institutional Ownership Trends
NUTX Short Interest
Shares sold short, counted twice a month.
27.18%
Short % of Float
of tradable shares sold short
1.3M
Shares Sold Short
+1.3% vs prior count
8.2 High
Days to Cover
trading days of normal volume to buy every short share back
152.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NUTX ranks across every disease it competes in
Competitive Position is a premium feature
See how NUTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNUTX News
-NUTX
Oct 19, 2026▼ -7.3%today
Nutex Health Schedules 2026 Third Quarter Financial Results Release and Conference Call
Nutex Health, Inc. plans to release its third quarter financial results on November 5, 2026, followed by a conference call on November 6 at 9:30 a.m. CT. The company operates 28 micro hospitals across 12 states and aims to provide a business update during the call. The announcement comes amid various operational risks and uncertainties.
Read more →-NUTX
Sep 22, 2026Nutex Health Approved for Dual Listing on Nasdaq Texas
Nutex Health Inc. has announced its approval for a dual listing on Nasdaq Texas, set to begin trading on September 23, 2026. This move aims to enhance the company's visibility among regional investors while maintaining its presence on the Nasdaq Global Market. The dual listing will not require any action from existing shareholders, ensuring full fungibility of shares across both venues.
Read more →-NUTX
Sep 10, 2026NUTEX HEALTH PROVIDES UPDATE REGARDING CYBERSECURITY EVENT
Nutex Health Inc. has provided an update on a cybersecurity event involving unauthorized access to its data. The company is currently assessing the scope and authenticity of the data published by the unauthorized party. Despite this incident, Nutex Health has not identified any material impact on its operations or financial reporting. The company is also facing class action lawsuits related to the breach.
Read more →-NUTX
Sep 2, 2026Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data
Nutex Health confirmed a serious data breach where unauthorized access led to the theft of sensitive patient and employee information. The ransomware group, The Gentlemen, has claimed responsibility and threatened to publish the stolen data. Affected individuals are at risk of identity theft, and a class action lawsuit has been initiated. Edelson Lechtzin LLP is investigating claims on behalf of those affected.
Read more →-NUTX
Aug 31, 2026Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026
Nutex Health Inc. announced that its hospitals earned several community honors in Q2 2026, reflecting their commitment to high-quality, patient-centered care. The awards, determined by local communities, highlight exceptional service and patient satisfaction across multiple facilities. Notable recognitions include Best ER and Best Hospital awards in various markets.
Read more →-NUTX
Aug 25, 2026Fifth Circuit Rejects "Ghost Rates" in Federal QPA Calculations Under the No Surprises Act
Nutex Health Inc. has welcomed a Fifth Circuit ruling that invalidates certain federal regulations affecting the calculation of the qualifying payment amount (QPA) under the No Surprises Act. The court found that the inclusion of non-negotiated 'ghost rates' in QPA calculations was unlawful, which has previously led to reduced payments for providers. This decision may lead to fairer payment practices, although the timeline for new regulations remains uncertain.
Read more →-NUTX
Aug 18, 2026NUTEX HEALTH OPENS WEST LITTLE ROCK EMERGENCY HOSPITAL IN ARKANSAS
Nutex Health Inc. has opened the West Little Rock Emergency Hospital, its 28th facility nationwide and third in Arkansas. The new hospital features advanced medical technology, including MRI and CT imaging, and offers 24/7 care. This facility aims to improve healthcare accessibility for families in Central Arkansas.
Read more →-NUTX
Aug 6, 2026▲ +6.7%on this news· ran to +30% by day 1
NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Nutex Health Inc. reported strong financial results for Q2 2026, with net income rising to $65.8 million and EBITDA reaching $94.1 million. Despite a 6.3% decrease in total revenue year-over-year, the company demonstrated improved operational efficiency and cash flow. The CFO expressed confidence in the company's growth trajectory, supported by upcoming hospital openings.
Read more →-NUTX
Jul 21, 2026Nutex Health Schedules 2026 Second Quarter Financial Results Release and Conference Call
Nutex Health, Inc. plans to release its second quarter financial results for 2026 on August 6, followed by a conference call on August 7 at 9:30 a.m. CT. The call will provide insights into the company's financial performance and business updates. Nutex operates 27 micro hospitals across 12 states, emphasizing its integrated healthcare delivery system.
Read more →-NUTX
Apr 30, 2026▲ +17.1%on this news
NUTEX HEALTH REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Nutex Health Inc. reported its financial results for Q1 2026, showing a 2.2% increase in total revenue to $216.5 million and a significant rise in net income to $46.8 million. The company also highlighted a strong operating cash flow of $75.5 million and plans to open three new hospitals later this year. The financial performance underscores Nutex's effective growth strategy and operational improvements.
Read more →-NUTX
Apr 22, 2026Nutex Health Schedules 2026 First Quarter Financial Results Release and Conference Call
Nutex Health, Inc. plans to release its first quarter financial results for 2026 on April 30, 2026, followed by a conference call on May 1, 2026, at 9:30 a.m. CT. The call will provide insights into the company's financial performance and business updates. Nutex operates a network of micro hospitals and physician groups across 12 states.
Read more →-NUTX
Mar 5, 2026▼ -14.3%on this news
NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
Nutex Health Inc. reported strong financial results for 2025, with total revenue reaching $875.3 million, an 82.4% increase from 2024. The company also announced a second stock repurchase program of up to $25 million. Despite a significant drop in fourth quarter revenue due to arbitration claims, the overall performance reflects robust growth and operational improvements. The company continues to expand its services with new micro-hospitals.
Read more →-NUTX
Feb 25, 2026▲ +6.7%on this news
Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call
Nutex Health, Inc. plans to file its Annual Report for the fiscal year ending December 31, 2025, on March 5, 2026. An earnings conference call is scheduled for March 6, 2026, at 9:30 a.m. CT to discuss financial results and provide a business update. The company operates 27 micro hospitals and outpatient departments across 12 states.
Read more →-NUTX
Jan 12, 2026NUTEX HEALTH RE-OPENS BAYOU CITY ER & HOSPITAL IN HOUSTON
Nutex Health Inc. has reopened Bayou City ER & Hospital in Humble, Texas, offering 24/7 concierge-level care. The facility includes advanced imaging technology and a full-service laboratory, aiming to meet the growing healthcare needs of the Northeast Houston community. Leadership emphasizes the importance of specialized services for unique patient needs.
Read more →-NUTX
Jan 5, 2026▲ +13.1%on this news· ran to +24% by day 3
NUTEX HEALTH TO ATTEND AND PRESENT AT THE 2026 J.P. MORGAN HEALTHCARE CONFERENCE IN JANUARY IN SAN FRANCISCO
Nutex Health Inc. announced its participation in the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12-15 in San Francisco. CEO Dr. Tom Vo, CFO Jon Bates, and President Dr. Warren Hosseinion will represent the company. The event highlights Nutex's integrated healthcare delivery system and its commitment to innovation in healthcare.
Read more →-NUTX
Dec 22, 2025NUTEX HEALTH OPENS ARCHVIEW ER & HOSPITAL IN ST. LOUIS
Nutex Health Inc. has opened its 26th hospital, Archview ER & Hospital, in St. Louis, Missouri. The facility features 15 emergency room beds and advanced imaging technology, offering 24/7 care to the community. The hospital aims to provide exceptional healthcare and is strategically located near significant landmarks, symbolizing innovation and accessibility.
Read more →-NUTX
Dec 4, 2025▲ +19%on this news
NUTEX HEALTH EXTENDS SHARE REPURCHASE PLAN
Nutex Health Inc. has announced an extension of its stock repurchase program, initially set to expire in December 2025, now extended through March 31, 2026. The program aims to repurchase up to $25 million of its common stock to enhance shareholder value and offset dilution from stock compensation obligations. This decision reflects the Board's confidence in the company's long-term strategy.
Read more →-NUTX
Nov 26, 2025NUTEX HEALTH RESPONDS TO SHORT SELLER REPORT
Nutex Health Inc. has responded to a short seller report from Capybara Research, which it claims lacks credibility. The company asserts that the report's allegations are based on outdated and inaccurate information. Nutex Health emphasizes its operational structure and ongoing legal disclosures while declining to comment further on the report.
Read more →About Nutex Health Inc. Common Stock
Headquarters1776 YORKTOWN ST, HOUSTON, TX, 77056
BIOPHARMAWATCH ELITE PLUS
Trade the next NUTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime